Table 1:

Demographics and baseline characteristics of enrolled patients

Characteristic	Cohort 1 VRP- HER2 (N = 4)	Cohort 2 VRP- HER2 + Anti-HER2 therapy (N = 18)	Total (N = 22)
Median Age at trial entry (Range)	58.5 (53-64)	59.0 (25–76)	59.0 (25–76)
Sex	No. (%)	No. (%)	No. (%)
Male	1 (25.0)	0 (0.0)	1 (4.5)
Female	3 (75.0)	18 (100.0)	21 (95.4)
Race
White	4 (100.0)	14 (77.8)	18 (81.8)
Nonwhite	0 (0.0)	4 (22.2)	4 (18.2)
HER2+ Disease Type
Breast Cancer	3 (75.0)	18 (100.0)	21 (95.4)
Esophageal Cancer	1 (25.0)	0 (0.0)	1 (4.5)
Hormone Receptor Status (BCa only)
HR+ (ER+ and or PR+	1 (33.3)	11 (61.1)	12 (57.1)
HR− (ER / PR−)	2 (66.7)	7 (38.9)	9 (42.9)
Years with metastatic disease
≤2 yrs	1 (25.0)	5 (27.8)	6 (27.2)
>2 yrs	3 (75.0)	13 (72.2)	16 (72.7)
Site(s) of metastasis (prior or current)
1-2	3 (75.0)	11 (61.1)	14 (63.6)
≥ 3	1 (25.0)	7 (38.9)	8 (36.3)
Prior Lines of Tx
1-2	1 (25.0)	8 (44.4)	9 (40.9)
3-5	2 (50.0)	4 (22.2)	6 (27.3)
>5	1 (25.0)	6 (33.3)	7 (31.8)
Prior Anti-HER2 Therapy
Trastuzumab	4 (100.0)	18 (100.0)	22 (100.0)
Pertuzumab + Trastuzumab	0 (0.0)	8 (44.4)	8 (36.3)
TDM-1	0 (0.0)	9 (50.0)	9 (40.9)
Lapatinib	3 (75%)	10 (55.6)	13 (59.1)